Tests ADX-038 in adults with complement-mediated kidney disease
Tests ADX-038 in adults with kidney diseases driven by the complement system.
Plain-language title generated from the registry record
Registry title: Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Key facts
- Where
- Barcelona, Madrid, and Seville, SpainSee the 3 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with IgAN, C3G or IC-MPGN, confirmed by a kidney biopsy, and with active kidney disease.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy, with clinical evidence of active kidney disease. Mean eGFR of 30 mL/min/1.73m2 or higher.
- Earlier treatment
- Must be treated with supportive care, including an ACE inhibitor or ARB if applicable. Must not have received complement inhibitor treatments. Must be willing to receive required vaccinations.
Main reasons for not taking part
- Hereditary or acquired complement deficiency
- Kidney transplant or renal replacement therapy
- History of solid organ transplant
- Other kidney disease
- History of recurrent invasive infections
Read by machine on 9 November 2026.
Where in Spain
- BarcelonaBarcelona, SpainTaking people
- MadridMadrid, SpainTaking people
- SevilleSeville, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ADARx Pharmaceuticals, Inc.
- Trial code
- NCT06989359
- Record updated
- 20 October 2026
- Original description
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.Read full original descriptionShow less
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Inclusion: Mean eGFR greater than or equal to 30 mL/min/1.73m2; Clinical evidence of active kidney disease; Treated with supportive care including an ACE inhibitor or ARB if applicable; Willing to receive required vaccinations; Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy.
Exclusion: Kidney transplant or renal replacement therapy; Received complement inhibitor treatments; History of solid organ transplant; Other kidney disease; History of recurrent invasive infections; Active systemic viral, bacterial, or fungal infection; Hereditary or acquired complement deficiency; Abnormal liver function.